• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Gastrointestinal

The following trials provide information to treat various types of gastrointestinal diseases, both for ongoing and completed clinical trials.  For more information on this therapy area please click here.

There are a number of ways to help you find trial information.  By using these filters you can find (i) recruiting status, (ii) therapy area, (iii) product and/or (iv) phase of drug development.  You can use one or all filters to identify your specific needs.

When a trial completes the results are reported here no later than one year after completion – this is why you may sometimes find that a Report is unavailable when you are searching through ‘closed’ trials.

  • Expand All
  • Collapse All
  • Pages
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • Next
  • collapse A randomized double-blind placebo-controlled study to assess the prevention of low-dose acetylsalicylic acid (ASA) associated gastroduodenal lesions and upper gastrointestinal symptoms in patients taking esomeprazole 20 mg once daily (od) for 26 weeks
  • collapse A randomised, double-blind, double dummy, multicentre study to evaluate the efficacy and safety of esomeprazole 40 mg given i.v. or orally o.d. for 1 week to subjects with erosive reflux esophagitis, followed by 3 weeks' open oral treatment with esomeprazole 40 mg o.d.
  • collapse A Randomised, Double-Blind, Placebo Controlled Explorative Study to Investigate the Efficacy and Safety of Esomeprazole in the Prevention of Post Operative Nausea and Vomiting
  • collapse An Open, Randomized, Two-Way Crossover Study Comparing the Effect of 20 mg Esomeprazole Administered Orally and Intravenously as a 3-minute Injection on Basal and Pentagastrin-Stimulated Acid Output in Patients with Symptoms of Gastroesophageal Reflux Disease (GERD)
  • expand An Open, Randomized, Two-Way Crossover Study Comparing the Effect of 40 mg Esomeprazole Administered Orally and Intravenously as a 3-minute Injection on Basal and Pentagastrin-Stimulated Acid Output in Patients with Symptoms of Gastroesophageal Reflux Disease (GERD)
    Study Id
    D9615C00013
    Disease
    gastrointestinal diseases
    Drug Name
    Nexium
    Study Name
    D9615C00013
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report
    Jan 18, 1971
    • D9615C00013.pdf (174 KB)
  • collapse A Phase III, Multicenter, Randomized, Double-blind, Parallel-group Study to Evaluate the Safety of Once Daily Esomeprazole for the Treatment of Clinically Diagnosed Gastroesophageal Reflux Disease (GERD) in Pediatric and Adolescent Patients 12 to 17 Years of Age, Inclusive
  • collapse A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years of Age, Inclusive
  • collapse A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Treatment-withdrawal Study to Evaluate the Efficacy and Safety of Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Infants Aged 1 to 11 Months, Inclusive
  • collapse A Randomized, Open-Label Study to Evaluate the Pharmacokinetics of Single Oral Doses of Esomeprazole Magnesium in Pediatric Patients 1 to 11 Years-Old Inclusive with Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)
  • collapse Randomised, double-blind, placebo-controlled multicenter study to assess management strategies in the treatment of Helicobacter pylori infected patients with gastro-oesophageal reflux disease (GERD)
  • Pages
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • Next
  • Expand All
  • Collapse All

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013